Medical Plus s.r.o. — Clinical Trial Site

46 Registered trials

8 Currently recruiting

Organisation

Medical Plus s.r.o.

Location

Uherske Hradiste, Czechia

Identifier

ORG-100042093

Address

Obchodni 1507, 686 01, Czechia

Departments

#2001: Revmatologicke a osteologicke centrum
#2003: Revmatologie
#2204: Revmatologie
#3053
#3202:Revmatologie
#40010
1604: Revmatologická ambulance
2001:Revmatologie
2001:Rheumatology
2002:Revmatologicke a osteologicke centrum
2041: Revmatologie
2102: Revmatologie
3053; Revmatologie
701_NA
7305
CZ10015
Medical Plus, s.r.o.
N/A
NA
Not applicable
Private rheumatology and osteology practice
Revmatologická ambulance
Revmatologie
Rheumatology

Clinical trials at this site (46)

Search interface

Guselkumab versus Placebo for the Treatment of Active Psoriatic Arthritis in Participants with Inadequate Response and/or Intolerance to One… Ended

2023-504715-33-00 Psoriatic Arthritis 5 2021-09-27
A Study of the Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis Ended

2023-504734-21-00 Psoriatic arthritis (PsA) 5 2021-08-30
Guselkumab versus Placebo for the Treatment of Psoriatic Arthritis Axial Disease in Bio-naive Participants Ended

2023-504716-15-00 Psoriatic Arthritis 6 2021-08-06
A Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or … Ended

2023-505478-14-00 Psoriatic Arthritis 5 2019-05-09
A Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Trial to Evaluate the Efficacy and Safety of Once Daily Diclofenac Gel AMZ001 … Ended

2024-517404-11-00 Knee Osteoarthritis 5 2025-04-30
A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy and safety of oral AP118… Ended

2024-514981-37-00 Rheumatoid Arthritis 4 2024-12-05
Study to evaluate the pharmacokinetics, safety and tolerability of Secukinumab in patients with GCA or PMR Ended

2023-507667-19-00 Polymyalgia rheumatica (PMR) 3 2024-06-06
A study to assess the efficacy and safety of tigulixostat at different doses as compared to a control drug (allopurinol) in gout patients wi… Ended

2022-501421-20-00 Gout with hyperuricemia 5 2024-04-09
A study to evaluate SAR441566 efficacy and safety in adults with rheumatoid arthritis Ended

2023-503910-60-00 Rheumatoid arthritis 4 2024-03-05
Tofacitinib in early active axial spondyloarthritis: a prospective, randomized, double-blind, placebo-controlled multicentre study - FASTLAN… Ended

2023-505050-18-00 Axial spondyloarthritis 6 2023-11-16
A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab a… Ended

2022-501895-25-00 Polymyalgia Rheumatica 5 2023-09-13
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis Ended

2022-502994-40-00 Rheumatoid Arthritis 4 2023-09-04
Two-arm study of the clinical efficacy, safety and tolerability of ianalumab (VAY736) in patients with active Sjögren’s syndrome Ended

2024-511069-12-00 Sjögren’s Syndrome 5 2022-07-28
Study of efficacy, safety and tolerability of DFV890 in patients with knee osteoarthritis Ended

2023-507559-30-00 Knee Osteoarthritis 4 2021-11-09
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Gia… Ended

2024-510744-31-00 Giant cell arteritis (GCA) 5 2021-10-06
Study of efficacy, safety, and tolerability of LNA043 in patients with symptomatic knee osteoarthritis Ended

2023-509937-37-00 Osteoarthritis 4 2021-07-21
An extension study to learn if Bimekizumab works and is safe over a long period in adults with Active Axial Spondyloarthritis. Ended

2023-506527-28-00 Axial Spondyloarthritis 5 2020-06-29
Evaluation of upadacitinib in adult subjects with axial spondyloarthritis Ended

2022-501018-78-00 Axial Spondyloarthritis 5 2020-03-23
Phase 3b/4 Study in Rheumatoid Arthritis Ended

2023-508022-10-00 Rheumatoid Arthritis 6 2019-07-25
A Phase 2a multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Burfiralimab (hzVSF-v13)… Ended

2023-507944-35-00 rheumatoid arthritis 4
A Randomized, Double-blind, Parallel-group, Active-controlled Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and… Ended

2024-512417-41-00 Osteoporosis 5
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Abiprubart i… Ended

2024-512986-15-00 Sjögren’s Disease 4